Susan Elisabeth Jorge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan Elisabeth Jorge has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Maria de Fatima Sonati
Univ Estadual Campinas, Fac Ciencias Med, Dept Patol Clin, Campinas, SP, Brazil
10 shared publications Fernando F. Costa
Univ Estadual Campinas, Ctr Hematol & Hemoterapia, Campinas, SP, Brazil
8 shared publicationsElza M. Kimura
Hemoglobinopathies Laboratory, Department of Clinical Pathology, School of Medical Sciences, State University of Campinas - UNICAMP, Campinas, São Paulo, Brazil
7 shared publicationsDulcinéia M. Albuquerque
Univ Estadual Campinas, Ctr Hematol & Hemoterapia, Campinas, SP, Brazil
6 shared publications- Daniel Botelho Costa
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
5 shared publications Denise M. Oliveira
5 shared publications
Latest Publications
- Open Access
- 7 December 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S158-S162
Functional characterization of compound heterozygosity Hb S/Hb Deer Lodge in Brazil
- 7 December 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S158-S162
Open AccessFunctional characterization of compound heterozygosity Hb S/Hb Deer Lodge in Brazil
- Open Access
- 28 November 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (1) , 14-21
Hemograms and serial hemogram-derived ratios in survivors and non-survivors of COVID-19 in Campinas, Brazil
- 28 November 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (1) , 14-21
Open AccessHemograms and serial hemogram-derived ratios in survivors and non-survivors of COVID-19 in Campinas, Brazil
- Open Access
- 13 December 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (24) , 6548-6555
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of advanced cancers with these mutations remains elusive, without an approved inhibitor. Experimental Design: Preclinical models of a representative set of EGFR exon 20 insertion mutations to evaluate the efficacy of different inhibitors and description of the clinical outcome of an advanced lung cancer. Results: We show that select first-, second-, and third-generation EGFR inhibitors are unable to deter common EGFR exon 20 insertion mutants in concentrations that spare the wild-type kinase. Nonetheless, EGFR exon 20 insertion mutants associate with the Hsp90 chaperone system. We exploit this vulnerability to show that the nongeldanamycin Hsp90 inhibitor luminespib (formerly AUY922) degrades EGFR exon 20 mutations, downstream targets, and induces apoptosis. In addition, a patient whose EGFR inhibitor–insensitive lung adenocarcinoma harbored an EGFR exon 20 insertion mutation had a confirmed radiographic response to luminespib. Conclusions: The report confirms that EGFR exon 20 mutations are dependent on Hsp90 and are readily inhibited by the Hsp90 inhibitor luminespib; a treatment strategy that has been pursued in a confirmatory clinical trial (NCT01854034) for this group of lung adenocarcinomas that currently represent an unmet clinical need in precision oncology.
- 13 December 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (24) , 6548-6555
Open AccessEGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of advanced cancers with these mutations remains elusive, without an approved inhibitor. Experimental Design: Preclinical models of a representative set of EGFR exon 20 insertion mutations to evaluate the efficacy of different inhibitors and description of the clinical outcome of an advanced lung cancer. Results: We show that select first-, second-, and third-generation EGFR inhibitors are unable to deter common EGFR exon 20 insertion mutants in concentrations that spare the wild-type kinase. Nonetheless, EGFR exon 20 insertion mutants associate with the Hsp90 chaperone system. We exploit this vulnerability to show that the nongeldanamycin Hsp90 inhibitor luminespib (formerly AUY922) degrades EGFR exon 20 mutations, downstream targets, and induces apoptosis. In addition, a patient whose EGFR inhibitor–insensitive lung adenocarcinoma harbored an EGFR exon 20 insertion mutation had a confirmed radiographic response to luminespib. Conclusions: The report confirms that EGFR exon 20 mutations are dependent on Hsp90 and are readily inhibited by the Hsp90 inhibitor luminespib; a treatment strategy that has been pursued in a confirmatory clinical trial (NCT01854034) for this group of lung adenocarcinomas that currently represent an unmet clinical need in precision oncology.
- 27 August 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (12) , e27413
Thalassemia major phenotype caused by HB Zürich‐Albisrieden [α2 59(E8) Gly > Arg (HBA2:C.178G > C)] in a Brazilian child
Hemoglobin (Hb) Zürich‐Albisrieden (ZA) [α2 59(E8) Gly > Arg; HBA2:c.178G > C] is a rare and highly unstable α‐chain variant. A few simple and compound heterozygotes (αZAα/αα and –/αZAα, respectively) have been described so far in Switzerland and China. We describe here a case of homozygosity for the Hb ZA mutation (αZAα/αZAα) in a Brazilian child with severe congenital hemolytic anemia and ineffective erythropoiesis.
- 27 August 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (12) , e27413
Thalassemia major phenotype caused by HB Zürich‐Albisrieden [α2 59(E8) Gly > Arg (HBA2:C.178G > C)] in a Brazilian child
Hemoglobin (Hb) Zürich‐Albisrieden (ZA) [α2 59(E8) Gly > Arg; HBA2:c.178G > C] is a rare and highly unstable α‐chain variant. A few simple and compound heterozygotes (αZAα/αα and –/αZAα, respectively) have been described so far in Switzerland and China. We describe here a case of homozygosity for the Hb ZA mutation (αZAα/αZAα) in a Brazilian child with severe congenital hemolytic anemia and ineffective erythropoiesis.
- 1 January 2018
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 637, 73-78
Understanding the molecular basis of the high oxygen affinity variant human hemoglobin Coimbra
- 1 January 2018
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 637, 73-78
Understanding the molecular basis of the high oxygen affinity variant human hemoglobin Coimbra
- 4 May 2017
- Published by Taylor & Francis in Hemoglobin
- Vol. 41 (3) , 203-208
Coinheritance of Hb Bristol-Alesha [β67(E11)Val→Met;HBB: c.202G>A] and the α212 Patchwork Allele in a Brazilian Child with Severe Congenital Hemolytic Anemia
Hb Bristol-Alesha [HBB: c.202G>A; β 67 Val>Met] is a rare structural variant of hemoglobin (Hb) resulting from a GTG>ATG substitution at codon 67 of the β-globin gene that leads to the replacement of valine by methionine in the corresponding position of the β-globin chain. The methionine residue is subsequently modified to aspartic acid [β67(E11)Val-Met→Asp], possibly by autoxidation mechanisms. This substitution prevents normal non-polar binding of Val67 to the heme group, resulting in molecular instability and severe hemolysis. We identified Hb Bristol-Alesha (in the heterozygous state), as the cause of severe congenital hemolytic anemia in an 11-month-old girl of mixed (native Indian and European) ethnic origin from the Midwestern region of Brazil, whose parents were clinically and hematologically normal. The mutation on the β-globin gene was found to have been coinherited with the α212 patchwork allele.
- 4 May 2017
- Published by Taylor & Francis in Hemoglobin
- Vol. 41 (3) , 203-208
Coinheritance of Hb Bristol-Alesha [β67(E11)Val→Met;HBB: c.202G>A] and the α212 Patchwork Allele in a Brazilian Child with Severe Congenital Hemolytic Anemia
Hb Bristol-Alesha [HBB: c.202G>A; β 67 Val>Met] is a rare structural variant of hemoglobin (Hb) resulting from a GTG>ATG substitution at codon 67 of the β-globin gene that leads to the replacement of valine by methionine in the corresponding position of the β-globin chain. The methionine residue is subsequently modified to aspartic acid [β67(E11)Val-Met→Asp], possibly by autoxidation mechanisms. This substitution prevents normal non-polar binding of Val67 to the heme group, resulting in molecular instability and severe hemolysis. We identified Hb Bristol-Alesha (in the heterozygous state), as the cause of severe congenital hemolytic anemia in an 11-month-old girl of mixed (native Indian and European) ethnic origin from the Midwestern region of Brazil, whose parents were clinically and hematologically normal. The mutation on the β-globin gene was found to have been coinherited with the α212 patchwork allele.
- 1 June 2016
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (6) , 918-923
Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas
- 1 June 2016
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (6) , 918-923
Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas
- 30 March 2016
- Published by Springer Nature
- p. 1-22
Hemoglobin: Structure, Synthesis and Oxygen Transport
- 30 March 2016
- Published by Springer Nature
- p. 1-22
Hemoglobin: Structure, Synthesis and Oxygen Transport
- 1 December 2015
- Published by Elsevier in Lung Cancer
- Vol. 90 (3) , 369-374
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
- 1 December 2015
- Published by Elsevier in Lung Cancer
- Vol. 90 (3) , 369-374
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
- Open Access
- 1 October 2015
- Published by Elsevier in SLAS Discovery
- Vol. 20 (9) , 1150-1159
A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation
- 1 October 2015
- Published by Elsevier in SLAS Discovery
- Vol. 20 (9) , 1150-1159
Open AccessA Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation